BROWNSTEIN HYATT FARBER SCHRECK, LLP for SAFE RX
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATE MCCANLESS BLANKENBURG | — |
| LAURA JOHNSON BOLLIER | — |
| ALEXANDER DAHL | — |
| PETER M. GOODLOE | — |
| ELIZABETH M GORE | — |
| MARC LAMPKIN | — |
| ELIZABETH ANNE MAIER | — |
| WILLIAM MOSCHELLA | — |
| ZACHARY PFISTER | — |
| NEIL F QUINTER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.